Childrens National Health System

Washington, DC, United States

Childrens National Health System

Washington, DC, United States
SEARCH FILTERS
Time filter
Source Type

WASHINGTON--(BUSINESS WIRE)--Registration is now open for the 2017 Race for Every Child, which benefits Children’s National Health System. The fifth annual 5K run/walk and Kids’ Dash will take place on Saturday, October 21, at Freedom Plaza in downtown Washington, DC. The Race for Every Child is one of the largest community events focused on children’s health in the Washington region. Proceeds will help save lives and build strong, healthy futures for children by supporting innovative therapies, research, wellness and education programs, and family support services. “As the premier provider of pediatric care in the Washington region, Children’s National is proud to host an event which reflects the importance of children, and children’s health, in our community and our nation,” said Dr. Kurt Newman, president and CEO of Children’s National. “Whether you are a serious runner, weekend jogger, a family that has been treated here or a community member coming out to support Children’s National, your participation in this event is making a tremendous impact on children’s health now and in the future.” Over the past four years, the Race for Every Child has become one of the area’s most popular family events, rallying a total of 10,850 runners and walkers and raising more than $4.3 million to help children grow up stronger. Proceeds from the Race for Every Child have helped Children’s National expand care for communities throughout Maryland, Virginia and Washington, DC. The goal for the 2017 Race for Every Child is to raise $1.5 million. Grace and Campbell Smith of Washington, DC return as co-chairs in 2017 and are joined by Melanie and Brigg Bunker of Potomac, Virginia. Both families credit the team at Children’s National for saving their children’s lives. “When our little girl needed expert care, Children’s National was there for us,” said Brigg and Melanie Bunker, 2017 Race for Every Child co-chairs. “The Race for Every Child is a way for us to say ‘thank you’ while having an amazing time with our family and friends. From the opportunity to meet your favorite superhero, to racing down 'America’s Main Street,' the Race for Every Child offers something fun for everyone.” Registration is now open at raceforeverychild.org and discounted early-bird registration rates will be available until June 15, 2017. Participants can create or join a team, sign up as an individual, or simply donate. The half-day event features a wide range of family-friendly activities at Freedom Plaza, including: The 2017 Race for Every Child is generously supported by sponsors CubeSmart, Costco Wholesale, The J. Willard and Alice S. Marriott Foundation, CBRE, Foulger-Pratt, Trammell Crow Company, Eastdil Secured, Clark Construction, Cushman & Wakefield, Inc., Quadrangle Development Corporation, The Annette M. and Theodore N. Lerner Family Foundation, Walgreens, CoStar Group, United Health Group, FTI Consulting, BKV Group, Buch Construction, Linowes & Blocher, LLP, HITT Contracting, Hoar Construction, The Chevy Chase Land Company, The JBG Companies, Whiting-Turner, Bryan Cave LLP, and Pioneer Building Services. To learn more about sponsorship opportunities, please contact Erica Baca at 301-565-8577 or ebaca@childrensnational.org. Children’s National Health System, based in Washington, D.C., has been serving the nation’s children since 1870. A Magnet® designated and Leapfrog Group Top Hospital, Children’s National was one of just four pediatric hospitals to rank in the top 20 in all 10 specialties evaluated in U.S. News & World Report 2016-17 Best Children’s Hospitals survey. With a community-based pediatric network, seven regional outpatient centers, an ambulatory surgery center, two emergency rooms, an acute care hospital, and collaborations throughout the region, Children’s National is recognized for its expertise and innovation in pediatric care and as an advocate for all children.


NCC-PDI, led by the Sheikh Zayed Institute and the A. James Clark School of Engineering at the University of Maryland, invites proposals from innovators – researchers, entrepreneurs and clinicians – with a pediatric medical device concept that has potential for commercialization. Competition finalists will pitch their medical device to a distinguished panel of judges at the symposium. In addition to the prize money, winners will receive consultation services from the FDA-funded consortium. For competition details and to apply, click here. "Receiving the symposium award was the start of great things for Velano, as it provided essential funding, expert services and validation that served as a bedrock for venture capital investment, FDA clearance and commercialization in hospitals nationwide," said Velano Vascular's Chief Executive Eric M. Stone, a winner of the 2014 competition and a member of the 2017 symposium planning committee. "The Sheikh Zayed Institute and the competition are critical to the future of innovation for pediatric devices and we are grateful for their support and efforts to help our kids." New this year, the nation's leading pediatric innovation symposium is co-locating in San Jose, Calif. in a joint effort with The MedTech Conference powered by AdvaMed – the premier gathering of medtech professionals in North America. "We are looking forward to holding our symposium on the West Coast this year," says Kolaleh Eskandanian, PhD, executive director of the Sheikh Zayed Institute and NCC-PDI. "We hope this move and collaboration with AdvaMed will create an opportunity for our audience to attend both events." She adds that the goal of the symposium's pitch competition is to provide financial support that will help bring pediatric devices to market faster by bridging the gap that often follows the prototyping phase in the device development life cycle. "At the 2014 Symposium, Velano Vascular's device, PIVO, was selected from among hundreds of applicants to win funding from the Sheikh Zayed Institute because of children's especially acute fear of needles," says Eskandanian. "We're so pleased with how far Velano has come in the last three years and are glad to have Eric on our planning committee." The one-day conference, located at the San Jose Convention Center, brings together medical device innovators, investors, researchers, clinicians and policy makers to stimulate pediatric device innovation and bring solutions to market faster for the benefit of children everywhere. This year's theme is "partnering for breakthroughs in pediatric surgery and care." For the symposium agenda and registration, visit www.pediatric-device-symposium.org. Children's National Health System, based in Washington, D.C., has been serving the nation's children since 1870. Children's National is #1 for babies and ranked in every specialty evaluated by U.S. News & World Report including placement in the top 10 for: Cancer (#7), Neurology and Neurosurgery (#9) Orthopedics (#9) and Nephrology (#10). Children's National has been designated two times as a Magnet® hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top NIH-funded pediatric institutions. Children's National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.


News Article | August 15, 2017
Site: www.prnewswire.com

As principal investigators, researchers at Children's Hospital of Philadelphia will lead the joint effort to build out the "Kids First" Data Resource Center. Children's National Health System in Washington, D.C., will spearhead specific projects, including the Open DIPG project, and as project ambassador will cultivate additional partnerships with public and private foundations and related research consortia to expand a growing trove of data about pediatric cancers and birth defects. "This is a tremendous opportunity for children and families whose lives have been forever altered by pediatric cancers," says Javad Nazarian, Ph.D., M.S.C., principal investigator in the Center for Genetic Medicine Research and scientific director of the Brain Tumor Institute at Children's National. "From just a dozen samples seven years ago, Children's National has amassed one of the nation's largest tumor biorepositories funded, in large part, by small foundations. Meanwhile, research teams have been sequencing data from samples here and around the world. With this infusion of federal funding, we are poised to turn these data into insights and to translate those research findings into effective treatments." Today's NIH grant builds on previous funding that Congress provided to the NIH Common Fund to underwrite research into structural birth defects and pediatric cancers. In the first phase, so-called X01 grantees—including Eric Vilain, M.D., Ph.D., newly named director of the Center for Genetic Medicine Research at Children's National—received funding to sequence genetic data from thousands of patients and families affected by childhood cancer and structural birth defects. This new phase of funding is aimed at opening access to those genetic sequences to a broader group of investigators around the globe by making hard-to-access data easily available on the cloud. The first project funded will be Open DIPG, run by Nazarian, a single disease prototype demonstrating how the new data resource center would work for multiple ailments. DIPG stands for diffuse intrinsic pontine glioma, aggressive pediatric brain tumors that defy treatment and are almost always fatal. Just as crowd sourcing can unleash the collective brainpower of a large group to untangle a problem swiftly, open data sharing could accomplish the same for childhood cancers, including DIPG. In addition to teasing out molecular alterations responsible for making such cancers particularly lethal, pooling data that now sits in silos could help to identify beneficial mutations that allow some children to survive months or years longer than others. "It's a question of numbers," Dr. Vilain says. "The bottom line is that making sense of the genomic information is significantly increased by working through large consortia because they provide access to many more patients with the disease. What is complicated about genetics is we all have genetic variations. The challenge we face is teasing apart regular genetic variations from those genetic variations that actually cause childhood cancers, including DIPG." Nazarian predicts some of the early steps for the research consortium will be deciding nuts-and-bolts questions faced by such a start-up venture, such as the best methods to provide data access, corralling the resources needed to store massive amounts of data, and providing data access and cross correlation. "One of the major challenges that the data resource center will face is to rapidly establish physical data storage space to store all of the data," Nazarian says. "We're talking about several petabytes—1,000 terabytes— of data. The second challenge to address will be data dissemination and, specifically, correlation of data across platforms representing different molecular profiles (genome versus proteome, for example). This is just the beginning, and it is fantastic to see a combination of public and private resources in answering these challenges." Related resources: Surviving pediatric diffuse intrinsic pontine glioma Pediatric research consortia unveil CAVATICA data platform Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma Children's National is part of a pediatric #cancer research collective awarded $14.8 million by NIH New data resource center for #cancer researchers promises to accelerate novel treatments for childhood tumors About Children's National Health System Children's National Health System, based in Washington, D.C., has been serving the nation's children since 1870. Children's National is #1 for babies and ranked in every specialty evaluated by U.S. News & World Report including placement in the top 10 for: Cancer (#7), Neurology and Neurosurgery (#9) Orthopedics (#9) and Nephrology (#10). Children's National has been designated two times as a Magnet®hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top NIH-funded pediatric institutions. Children's National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter. About Kids First The Common Fund's Gabriella Miller Kids First Pediatric Research Program will capitalize on exciting advances in genetics research by developing a large-scale data resource. The resource will allow researchers everywhere access to vast amounts of childhood cancer and structural birth defects genetics data that will greatly accelerate their research.


Led by researchers at Children's National Health System, this is the first randomized two-group study to document the effectiveness of Mindfulness-Based Stress Reduction (MBSR) and online video support groups in lowering illness-related stress for youth with heart conditions. Beyond stress reduction, the study also found that greater use of coping skills predicted lower levels of depression for participants following the interventions. Additionally, patients with higher levels of anxiety and depression pre-intervention recorded the biggest improvements post-study. "Being a teenager is hard enough, but being the only person you know with a potentially life-threating heart condition can be devastating," says Vicki Freedenberg, RN, Ph.D., electrophysiology nurse within the Children's National Heart Institute and the principal investigator for the study. "These results indicate that teaching patients coping skills and connecting them with their peers can not only reduce their stress levels now, but these tools could also dramatically improve their responses to stressors for the rest of their lives." MBSR employs psycho-educational tools, including yoga, meditation, group support, and other mindful approaches to dealing with stressors – which, for teens with heart conditions, could translate to better coping techniques when anxiety and heart palpitations strike. Participants were randomly assigned to the MBSR group or the video online support group for the six-week study. The study included 46 adolescents, ages 12 to 18, with congenital heart disease, cardiac arrhythmias, cardiac devices or postural orthostatic tachycardia syndrome. Before and after the study period, patients self-reported illness-related stress and coping using the Responses to Stress Questionnaire, as well as anxiety and depression levels using the Hospital Anxiety and Depression Scale. Participants in the MBSR group met in person for 90 minutes once a week. During the sessions, the study's lead author led the teens through mindfulness exercises and facilitated group discussions, focusing on fears and stressors related to body image, as well as heart conditions and associated devices. The online support group used Skype to connect with peers for one hour each week. During the first half of each session, Freedenberg moderated group discussions about cardiac-related health topics requested by the participants, and the last 30 minutes were spent in open discussion on any topic – often ranging from issues at school to sports and entertainment. "We are encouraged by our initial findings, and they indicate that we need to further study and understand the impact of behavioral and psychosocial interventions in adolescents with cardiac diagnoses," says Freedenberg. "Adult studies have shown similar interventions can reduce risk for mortality and stroke among cardiac patients, and we are hopeful that further research will show equally positive findings for teens." Children's National Health System, based in Washington, D.C., has been serving the nation's children since 1870. Children's National is #1 for babies and ranked in every specialty evaluated by U.S. News & World Report including placement in the top 10 for:  Cancer (#7), Neurology and Neurosurgery (#9) Orthopedics (#9) and Nephrology (#10). Children's National has been designated two times as a Magnet® hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers. Home to the Children's Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National is one of the nation's top NIH-funded pediatric institutions. Children's National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.


WASHINGTON, Nov. 29, 2016 /PRNewswire-USNewswire/ -- Children's National Health System announces the launch of a major three-year research study of undiagnosed diseases in partnership with the Regeneron Genetics Center (RGC, a subsidiary of Regeneron Pharmaceuticals, Inc.). The research...


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announced its support for Rare Disease Day by making a gift to newly formed Children’s National Rare Disease Institute (CNRDI). This gift will go toward the CNRDI’s Innovation Fund, which supports new projects including diagnostics, devices, research, therapeutics, and process engineering, which will help advance the care and experience for children with rare diseases. “We are grateful for Cydan’s support of the Children’s National Rare Disease Institute,” said Marshall Summar, MD, chief of Genetics and Metabolism at Children’s National and chairman of the board at the National Organization for Rare Disorders (NORD). “With philanthropic investments from companies like Cydan, we will redefine the standard of care for children with genetic disorders, especially those largely unknown to the general medical community.” Chris Adams, Ph.D., co-founder and chief executive officer at Cydan, said, “We are proud to support Children’s National and this first-of-its-kind center in the U.S. focused exclusively on advancing the care and treatment of children and adults with rare genetic diseases. Rare diseases affect approximately 30 million Americans, and it’s heartening to see more resources dedicated to the identification, treatment and cure of these disorders.” As one of the first philanthropic contributions to the CNRDI Innovation Fund, Cydan’s gift will help to serve as a catalyst for rare disease care initiatives and help create an ever-expanding clinical knowledge base that advances the testing and development of rare disease therapies. Rare Disease Day® is an annual awareness day celebrated worldwide. This day is dedicated to elevating public understanding of rare diseases and calling attention to the special challenges faced by patients and their families. Rare Disease Day takes place every year on the last day of February to underscore the scientific, medical and social issues that affect this population. It was established in Europe in 2008 by EURORDIS, the organization representing rare disease patients in Europe, and is now observed in more than 80 nations. Rare Disease Day is sponsored by the National Organization for Rare Disorders® (NORD®), a leading independent, nonprofit organization committed to the identification, treatment, and cure of rare diseases. Cydan is an orphan drug accelerator dedicated to delivering therapies that will significantly improve the lives of people living with rare genetic diseases. Cydan evaluates experimental new therapies and advances those with the highest potential to be disease modifying treatments. Cydan’s goal is to launch new companies focused on developing promising therapies for rare genetic diseases with high unmet medical need. Vtesse, Cydan’s first new company, was launched in January 2015 and is developing a novel therapy for Niemann-Pick Disease Type C (NPC). Imara was launched in 2016 and is developing a novel treatment for Sickle Cell disease. Cydan was founded in 2013 by a management team with extensive drug discovery, clinical development and business development experience and financed by leading life sciences investors NEA, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. The accelerator is based in Tech Square in Cambridge, Mass. For more information, visit http://www.cydanco.com or contact Cydan at info@cydanco.com. Children’s National Health System, based in Washington, DC, has been serving the nation’s children since 1870. Children’s National is ranked in the top 20 in every specialty evaluated by U.S. News & World Report; one of only four children’s hospitals in the nation to earn this distinction. Designated a Leapfrog Group Top Hospital and a two-time recipient of Magnet® status, this pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is one of the nation’s top NIH-funded pediatric institutions. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. For more information, visit ChildrensNational.org.


WASHINGTON--(BUSINESS WIRE)--Emerging data from Children’s National Health System are providing hope that a new approach to cell therapy may effectively harness the cancer-killing potential of the natural immune system as a treatment for patients with blood and bone marrow cancers for whom stem cell transplantation has not worked. These patients typically have few treatment options and experience very high mortality rates. Initial results from the Phase 1 RESOLVE trial, a multi-institutional, Phase 1 dose-ranging study co-led by Kirsten Williams, M.D., and Catherine Bollard, M.D., M.B.Ch.B., Chief of the Division of Allergy and Immunology and Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) at Children’s National, showed that the majority (78 percent) of patients responded to multi tumor-associated antigen specific lymphocytes (TAA-L) treatment, and 44 percent of patients achieved complete remission with limited toxicity. The trial included patients diagnosed with one of four tumors who were treated with TAA-L upon relapse of disease post stem cell transplant. “These initial findings suggest that non-genetically engineered antigen-specific lymphocytes can be isolated, expanded and adoptively transferred to severely ill patients with active disease and positively impact tumor regression,” says Dr. Bollard. “We are encouraged by the promise of these data, which support similar efforts to exploit the immunotherapeutic potential of the natural T-cell repertoire.” The data, presented at the BMT Tandem meeting in Orlando, Florida, was a collaboration between investigators at Children’s National and researchers at Johns Hopkins University and Baylor College of Medicine who are testing a novel approach to treating cancer. Their approach includes introducing TAA-L – a natural T-cell subtype from the immune system – to high-risk patients with advanced hematologic or blood cancers including acute myeloid leukemia (AML)/ Myelodysplastic Syndromes (MDS), B-cell acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma. The trial evaluates the safety and efficacy of both donor and patient-derived TAA-L as a novel treatment for patients with AML/MDS, B-cell ALL or Hodgkin lymphoma who are in active disease relapse pre- or post-allogeneic hematopoietic stem cell transplantation (HSCT). Patients with refractory and relapsed AML, MDS, ALL and Hodgkin lymphoma often have extremely poor clinical outcomes. For patients with these malignancies who relapse after allogeneic stem cell transplantation, the prognosis is even more dismal. Sadly, one-year mortality rates for this population approach 90 percent. The results include patients receiving adoptively transferred TAA-L manufactured cells across all dosing cohorts allowed per protocol (dose levels one through four), 10 patients in total. Preliminary observations conclude that ex vivo manufactured TAA-L, composed primarily of central effector memory T-cells, can be successfully isolated and expanded to clinically relevant numbers, cryopreserved, and safely infused to patients after relapse of disease. There were no cases of graft-versus-host disease or other autoimmune-mediated toxicity reported, and there have been no observations of Cytokine Release Syndrome or neurotoxicity associated with TAA-L treatment. The RESOLVE trial has been and/or is funded by a National Institutes of Health grant (P01CA015396), the Leukemia Lymphoma Society, Ben’s Run and Hyundai Hope on Wheels. The BMT Tandem meeting is the combined annual meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation. Children’s National Health System, based in Washington, DC, has been serving the nation’s children since 1870. Children’s National is ranked in the top 20 in every specialty evaluated by U.S. News & World Report; one of only four children’s hospitals in the nation to earn this distinction. Designated a Leapfrog Group Top Hospital and a two-time recipient of Magnet® status, this pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is one of the nation’s top NIH-funded pediatric institutions. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. For more information, visit ChildrensNational.org, or follow us on Facebook and Twitter.


News Article | March 1, 2017
Site: www.prnewswire.com

WASHINGTON, March 1, 2017 /PRNewswire-USNewswire/ -- First Lady Melania Trump today met with patients, families, doctors and other care team members at Children's National Health System, to talk about their personal experiences and health care journeys, and how the gift of nature and the...


Russell Cruz C.,Childrens National Health System | Bollard C.M.,Childrens National Health System
Haematologica | Year: 2015

Hematopoietic stem cell transplantation has revolutionized the treatment of hematologic malignancies, but infection, graft-versus-host disease and relapse are still important problems. Calcineurin inhibitors, T-cell depletion strategies, and immunomodulators have helped to prevent graft-versus-host disease, but have a negative impact on the graft-versus-leukemia effect. T cells and natural killer cells are both thought to be important in the graft-versus-leukemia effect, and both cell types are amenable to ex vivo manipulation and clinical manufacture, making them versatile immunotherapeutics. We provide an overview of these immunotherapeutic strategies following hematopoietic stem cell transplantation, with discussions centered on natural killer and T-cell biology. We discuss the contributions of each cell type to graft-versus-leukemia effects, as well as the current research directions in the field as related to adoptive cell therapy after hematopoietic stem cell transplantation. © 2015 Ferrata Storti Foundation.


Su L.,Childrens National Health System
Current Problems in Pediatric and Adolescent Health Care | Year: 2015

Since humans are an integral part of healthcare delivery, it is appropriate to understand how human nature and human error impact patient safety. A thorough understanding of the interactions between humans and the medical environment could help decrease errors that result in patient harm. This article describes some of our findings from a study that revealed unexpected behaviors which were documented on video during critical events (cardiac arrests) in a pediatric cardiac intensive care unit (CICU). We changed our training process for cardiac arrests as well as our nurse staffing in the CICU based upon results of our study. We believe that the lessons learned in our CICU are generalizable to both inpatient and ambulatory settings. We also emphasize the importance of collaborating with social scientists to rigorously study innate maladaptive patterns of human behavior to determine strategies to mitigate "human factors" during acute medical crises. © 2015 Mosby, Inc. All rights reserved.

Loading Childrens National Health System collaborators
Loading Childrens National Health System collaborators